The agency’s decision, announced Thursday, allows Tudriqev — previously known as RP1 — to be used in combination with Bristol Myers Squibb’s immunotherapy for patients facing limited treatment options. The approval marks a turning point for Replimune, a Massachusetts-based company that had repeatedly failed to convince regulators of its drug’s readiness for market.
What Tudriqev Does
Tudriqev belongs to a class of therapies called oncolytic viruses — engineered viruses designed to infect and destroy cancer cells while simultaneously triggering the body’s immune system to attack tumors. Replimune has spent years developing the platform, betting that a modified virus could offer a new avenue for patients whose skin cancer has resisted standard treatments.
The drug is administered in combination with Bristol Myers Squibb’s Opdivo, a checkpoint inhibitor already widely used across several cancer types. The pairing is aimed at advanced skin cancers where surgery and conventional immunotherapy have run their course.
A Long Road to Approval
Replimune’s path to its first marketed product was anything but smooth. The company had faced multiple regulatory setbacks before this approval, with earlier attempts falling short of FDA requirements. Those prior rejections had weighed on investor confidence and raised questions about whether the oncolytic virus approach could clear the high bar set by U.S. regulators.
For Replimune, which had no products on the market, the FDA’s green light represents more than a scientific milestone — it is a commercial lifeline. The approval transforms the firm from a clinical-stage biotech into a revenue-generating company, a transition that often determines survival in the high-burn pharmaceutical sector.
Skin Cancer Treatment Landscape
Skin cancer remains the most commonly diagnosed cancer in the United States, with advanced forms such as melanoma posing significant treatment challenges once the disease spreads beyond the skin. While checkpoint inhibitors like Opdivo and Merck’s Keytruda have reshaped the melanoma treatment paradigm over the past decade, a meaningful share of patients do not respond or eventually relapse.
This unmet need has driven interest in combination strategies that pair existing immunotherapies with novel agents. Oncolytic viruses represent one such approach, and Tudriqev’s approval adds a new tool to the combination toolkit. Other companies, including Iovance Biotherapeutics, have also been pursuing cell-based therapies for skin cancer, signaling a broader industry push into hard-to-treat oncology indications.
What Happens Next
Replimune must now execute a commercial launch — no small task for a company entering the market for the first time. Pricing, payer negotiations, and physician adoption will all determine how quickly Tudriqev reaches patients and whether it generates meaningful revenue. Analysts will be watching early prescription trends for signals about uptake.
Regulators may also require post-approval studies to confirm Tudriqev’s clinical benefit, a common condition for accelerated approvals. Replimune will need to deliver follow-up data that holds up under scrutiny, especially given its history of regulatory disappointment. Meanwhile, the broader oncolytic virus field will be watching closely: Tudriqev’s commercial performance could either validate the platform or reinforce skepticism that has shadowed it for years.
— Aisha Mensah, health desk, AXO News